Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. (PFE) Net income
Pfizer Inc.'s net income for fiscal 2025 was $7.8B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.4B. Over the past ten years it has ranged from $2.2B (fiscal 2023) to $31.4B (fiscal 2022); the current reading is higher than 36% of that period. Pfizer Inc. ranks 11th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $7.8B | (3.10%) |
| FY2024 | $8.1B | 273.59% |
| FY2023 | $2.2B | (93.13%) |
| FY2022 | $31.4B | 42.60% |
| FY2021 | $22.0B | 139.53% |
| FY2020 | $9.2B | (42.73%) |
| FY2019 | $16.1B | 43.51% |
| FY2018 | $11.2B | (47.61%) |
| FY2017 | $21.4B | 194.71% |
| FY2016 | $7.2B | 3.72% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$238.0M | — |
| Mar 2026 | $2.7B | — |
| Dec 2025 | −$1.6B | — |
| Sep 2025 | $3.6B | 21.28% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| AMGN Amgen Inc. compare | $8.7B |
| GSK GSK PLC Sponsored ADR compare | $6.9B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. | $4.4B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on PFE
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement